Skip to main content
Top
Published in: Critical Care 3/2014

Open Access 01-06-2014 | Research

β-lactam antibiotic concentrations during continuous renal replacement therapy

Authors: Marjorie Beumier, Giuseppe Stefano Casu, Maya Hites, Lucie Seyler, Frederic Cotton, Jean-Louis Vincent, Frédérique Jacobs, Fabio Silvio Taccone

Published in: Critical Care | Issue 3/2014

Login to get access

Abstract

Introduction

The use of standard doses of β-lactam antibiotics during continuous renal replacement therapy (CRRT) may result in inadequate serum concentrations. The aim of this study was to evaluate the adequacy of unadjusted drug regimens (i.e., similar to those used in patients with normal renal function) in patients treated with CRRT and the influence of CRRT intensity on drug clearance.

Methods

We reviewed data from 50 consecutive adult patients admitted to our Department of Intensive Care in whom routine therapeutic drug monitoring (TDM) of broad-spectrum β-lactam antibiotics (ceftazidime or cefepime, CEF; piperacillin/tazobactam; TZP; meropenem, MEM) was performed using unadjusted β-lactam antibiotics regimens (CEF = 2 g q8h; TZP = 4 g q6h; MEM = 1 g q8h). Serum drug concentrations were measured twice during the elimination phase by high-performance liquid chromatography (HPLC-UV). We considered therapy was adequate when serum drug concentrations were between 4 and 8 times the minimal inhibitory concentration (MIC) of Pseudomonas aeruginosa during optimal periods of time for each drug (≥70% for CEF; ≥ 50% for TZP; ≥ 40% for MEM). Therapy was considered as early (ET) or late (LT) phase if TDM was performed within 48 hours of antibiotic initiation or later on, respectively.

Results

We collected 73 serum samples from 50 patients (age 58 ± 13 years; Acute Physiology and Chronic Health Evaluation II (APACHE II) score on admission 21 (17–25)), 35 during ET and 38 during LT. Drug concentrations were above 4 times the MIC in 63 (90%), but above 8 times the MIC in 39 (53%) samples. The proportions of patients with adequate drug concentrations during ET and LT were quite similar. We found a weak but significant correlation between β-lactam antibiotics clearance and CRRT intensity.

Conclusions

In septic patients undergoing CRRT, doses of β-lactam antibiotics similar to those given to patients with normal renal function achieved drug levels above the target threshold in 90% of samples. Nevertheless, 53% of samples were associated with very high drug levels and daily drug regimens may need to be adapted accordingly.
Appendix
Available only for authorised users
Literature
1.
go back to reference Vincent JL, Rello J, Marshall J, Silva E, Anzueto A, Martin CD, Moreno R, Lipman J, Gomersall C, Sakr Y, Reinhart K, EPIC II, Group of Investigators: International study of the prevalence and outcomes of infection in intensive care units. JAMA 2009, 302: 2323-2329. 10.1001/jama.2009.1754PubMedCrossRef Vincent JL, Rello J, Marshall J, Silva E, Anzueto A, Martin CD, Moreno R, Lipman J, Gomersall C, Sakr Y, Reinhart K, EPIC II, Group of Investigators: International study of the prevalence and outcomes of infection in intensive care units. JAMA 2009, 302: 2323-2329. 10.1001/jama.2009.1754PubMedCrossRef
2.
go back to reference Brun-Buisson C: The epidemiology of the systemic inflammatory response. Intensive Care Med 2000, 26: S64-S74. 10.1007/s001340051121PubMedCrossRef Brun-Buisson C: The epidemiology of the systemic inflammatory response. Intensive Care Med 2000, 26: S64-S74. 10.1007/s001340051121PubMedCrossRef
3.
go back to reference Kumar A, Roberts D, Wood KE, Light B, Parrillo JE, Sharma S, Suppes R, Feinstein D, Zanotti S, Taiberg L, Gurka D, Kumar A, Cheang M: Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006, 34: 1589-1596. 10.1097/01.CCM.0000217961.75225.E9PubMedCrossRef Kumar A, Roberts D, Wood KE, Light B, Parrillo JE, Sharma S, Suppes R, Feinstein D, Zanotti S, Taiberg L, Gurka D, Kumar A, Cheang M: Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006, 34: 1589-1596. 10.1097/01.CCM.0000217961.75225.E9PubMedCrossRef
4.
go back to reference Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, Sevransky JE, Sprung CL, Douglas IS, Jaeschke R, Osborn TM, Nunnally ME, Townsend SR, Reinhart K, Kleinpell RM, Angus DC, Deutschman CS, Machado FR, Rubenfeld GD, Webb S, Beale RJ, Vincent JL, Moreno R, Surviving Sepsis Campaign Guidelines Committee including The Pediatric Subgroup: Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med 2013, 39: 165-228. 10.1007/s00134-012-2769-8PubMedCrossRef Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, Sevransky JE, Sprung CL, Douglas IS, Jaeschke R, Osborn TM, Nunnally ME, Townsend SR, Reinhart K, Kleinpell RM, Angus DC, Deutschman CS, Machado FR, Rubenfeld GD, Webb S, Beale RJ, Vincent JL, Moreno R, Surviving Sepsis Campaign Guidelines Committee including The Pediatric Subgroup: Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med 2013, 39: 165-228. 10.1007/s00134-012-2769-8PubMedCrossRef
5.
go back to reference Kollef MH, Sherman G, Ward S, Fraser VJ: Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 1999, 115: 462-474. 10.1378/chest.115.2.462PubMedCrossRef Kollef MH, Sherman G, Ward S, Fraser VJ: Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 1999, 115: 462-474. 10.1378/chest.115.2.462PubMedCrossRef
6.
go back to reference Zaragoza R, Artero A, Camarena JJ, Sancho S, González R, Nogueira JM: The influence of inadequate empirical antimicrobial treatment on patients with bloodstream infections in an intensive care unit. Clin Microbiol Infect 2003, 9: 412-418. 10.1046/j.1469-0691.2003.00656.xPubMedCrossRef Zaragoza R, Artero A, Camarena JJ, Sancho S, González R, Nogueira JM: The influence of inadequate empirical antimicrobial treatment on patients with bloodstream infections in an intensive care unit. Clin Microbiol Infect 2003, 9: 412-418. 10.1046/j.1469-0691.2003.00656.xPubMedCrossRef
7.
go back to reference Pinder M, Bellomo R, Lipman J: Pharmacological principles of antibiotic prescription in the critically ill. Anaesth Intensive Care 2002, 30: 134-144.PubMed Pinder M, Bellomo R, Lipman J: Pharmacological principles of antibiotic prescription in the critically ill. Anaesth Intensive Care 2002, 30: 134-144.PubMed
8.
go back to reference Adnan S, Li JX, Wallis SC, Rudd M, Jarrett P, Paterson DL, Lipman J, Udy AA, Roberts JA: Pharmacokinetics of meropenem and piperacillin in critically ill patients with indwelling surgical drains. Int J Antimicrob Agents 2013, 42: 90-93. 10.1016/j.ijantimicag.2013.02.023PubMedCrossRef Adnan S, Li JX, Wallis SC, Rudd M, Jarrett P, Paterson DL, Lipman J, Udy AA, Roberts JA: Pharmacokinetics of meropenem and piperacillin in critically ill patients with indwelling surgical drains. Int J Antimicrob Agents 2013, 42: 90-93. 10.1016/j.ijantimicag.2013.02.023PubMedCrossRef
9.
go back to reference Heinemeyer G, Link J, Weber W, Meschede V, Roots I: Clearance of ceftriaxone in critical care patients with acute renal failure. Intensive Care Med 1990, 16: 448-453. 10.1007/BF01711224PubMedCrossRef Heinemeyer G, Link J, Weber W, Meschede V, Roots I: Clearance of ceftriaxone in critical care patients with acute renal failure. Intensive Care Med 1990, 16: 448-453. 10.1007/BF01711224PubMedCrossRef
10.
go back to reference Trotman RL, Williamson JC, Shoemaker DM, Salzer WL: Antibiotic dosing in critically ill adult patients receiving continuous renal replacement therapy. Clin Infect Dis 2005, 41: 1159-1166. 10.1086/444500PubMedCrossRef Trotman RL, Williamson JC, Shoemaker DM, Salzer WL: Antibiotic dosing in critically ill adult patients receiving continuous renal replacement therapy. Clin Infect Dis 2005, 41: 1159-1166. 10.1086/444500PubMedCrossRef
11.
go back to reference Matzke GR, Frye RF, Joy MS, Palevsky PM: Determinants of ceftazidime clearance by continuous venovenous hemofiltration and continuous venovenous hemodialysis. Antimicrob Agents Chemother 2000, 44: 1639-1644. 10.1128/AAC.44.6.1639-1644.2000PubMedPubMedCentralCrossRef Matzke GR, Frye RF, Joy MS, Palevsky PM: Determinants of ceftazidime clearance by continuous venovenous hemofiltration and continuous venovenous hemodialysis. Antimicrob Agents Chemother 2000, 44: 1639-1644. 10.1128/AAC.44.6.1639-1644.2000PubMedPubMedCentralCrossRef
12.
go back to reference Mueller SC, Majcher-Peszynska J, Hickstein H, Francke A, Pertschy A, Schulz M, Mundkowski R, Drewelow B: Pharmacokinetics of piperacillin-tazobactam in anuric intensive care patients during continuous venovenous hemodialysis. Antimicrob Agents Chemother 2002, 46: 1557-1560. 10.1128/AAC.46.5.1557-1560.2002PubMedPubMedCentralCrossRef Mueller SC, Majcher-Peszynska J, Hickstein H, Francke A, Pertschy A, Schulz M, Mundkowski R, Drewelow B: Pharmacokinetics of piperacillin-tazobactam in anuric intensive care patients during continuous venovenous hemodialysis. Antimicrob Agents Chemother 2002, 46: 1557-1560. 10.1128/AAC.46.5.1557-1560.2002PubMedPubMedCentralCrossRef
13.
go back to reference Valtonen M, Tiula E, Backman JT, Neuvonen PJ: Elimination of meropenem during continuous veno-venous haemofiltration and haemodiafiltration in patients with acute renal failure. J Antimicrob Chemother 2000, 45: 701-704. 10.1093/jac/45.5.701PubMedCrossRef Valtonen M, Tiula E, Backman JT, Neuvonen PJ: Elimination of meropenem during continuous veno-venous haemofiltration and haemodiafiltration in patients with acute renal failure. J Antimicrob Chemother 2000, 45: 701-704. 10.1093/jac/45.5.701PubMedCrossRef
14.
go back to reference Roberts DM, Roberts JA, Roberts MS, Liu X, Nair P, Cole L, Lipman J, Bellomo R, RENAL Replacement Therapy Study Investigators: Variability of antibiotic concentrations in critically ill patients receiving continuous renal replacement therapy: a multicentre pharmacokinetic study. Crit Care Med 2012, 40: 1523-1528. 10.1097/CCM.0b013e318241e553PubMedCrossRef Roberts DM, Roberts JA, Roberts MS, Liu X, Nair P, Cole L, Lipman J, Bellomo R, RENAL Replacement Therapy Study Investigators: Variability of antibiotic concentrations in critically ill patients receiving continuous renal replacement therapy: a multicentre pharmacokinetic study. Crit Care Med 2012, 40: 1523-1528. 10.1097/CCM.0b013e318241e553PubMedCrossRef
15.
go back to reference Seyler L, Cotton F, Taccone FS, De Backer D, Macours P, Vincent JL, Jacobs F: Recommended β-lactam regimens are inadequate in septic patients treated with continuous renal replacement therapy. Crit Care 2011, 15: R137. 10.1186/cc10257PubMedPubMedCentralCrossRef Seyler L, Cotton F, Taccone FS, De Backer D, Macours P, Vincent JL, Jacobs F: Recommended β-lactam regimens are inadequate in septic patients treated with continuous renal replacement therapy. Crit Care 2011, 15: R137. 10.1186/cc10257PubMedPubMedCentralCrossRef
16.
go back to reference Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, Cohen J, Opal SM, Vincent JL, Ramsay G: International Sepsis Definitions Conference. Intensive Care Med 2003, 29: 530-538. 10.1007/s00134-003-1662-xPubMedCrossRef Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, Cohen J, Opal SM, Vincent JL, Ramsay G: International Sepsis Definitions Conference. Intensive Care Med 2003, 29: 530-538. 10.1007/s00134-003-1662-xPubMedCrossRef
17.
go back to reference van der Werf TS, Mulder PO, Zijlstra JG, Uges DR, Stegeman CA: Pharmacokinetics of piperacillin and tazobactam in critically ill patients with renal failure, treated with continuous veno-venous hemofiltration (CVVH). Intensive Care Med 1997, 23: 873-877. 10.1007/s001340050424PubMedCrossRef van der Werf TS, Mulder PO, Zijlstra JG, Uges DR, Stegeman CA: Pharmacokinetics of piperacillin and tazobactam in critically ill patients with renal failure, treated with continuous veno-venous hemofiltration (CVVH). Intensive Care Med 1997, 23: 873-877. 10.1007/s001340050424PubMedCrossRef
18.
go back to reference Malone RS, Fish DN, Abraham E, Teitelbaum I: Pharmacokinetics of cefepime during continuous renal replacement therapy in critically ill patients. Antimicrob Agents Chemother 2001, 45: 3148-3155. 10.1128/AAC.45.11.3148-3155.2001PubMedPubMedCentralCrossRef Malone RS, Fish DN, Abraham E, Teitelbaum I: Pharmacokinetics of cefepime during continuous renal replacement therapy in critically ill patients. Antimicrob Agents Chemother 2001, 45: 3148-3155. 10.1128/AAC.45.11.3148-3155.2001PubMedPubMedCentralCrossRef
19.
go back to reference Wolff F, Deprez G, Seyler L, Taccone F, Hites M, Gulbis B, Vincent JL, Jacobs F, Cotton F: Rapid quantification of six β-lactams to optimize dosage regimens in severely septic patients. Talanta 2013, 103: 153-160.PubMedCrossRef Wolff F, Deprez G, Seyler L, Taccone F, Hites M, Gulbis B, Vincent JL, Jacobs F, Cotton F: Rapid quantification of six β-lactams to optimize dosage regimens in severely septic patients. Talanta 2013, 103: 153-160.PubMedCrossRef
21.
go back to reference Choi G, Gomersall CD, Tian Q, Joynt GM, Freebairn R, Lipman J: Principles of antibacterial dosing in continuous renal replacement therapy. Crit Care Med 2009, 37: 2268-2282. 10.1097/CCM.0b013e3181aab3d0PubMedCrossRef Choi G, Gomersall CD, Tian Q, Joynt GM, Freebairn R, Lipman J: Principles of antibacterial dosing in continuous renal replacement therapy. Crit Care Med 2009, 37: 2268-2282. 10.1097/CCM.0b013e3181aab3d0PubMedCrossRef
22.
go back to reference Ververs TF, van Dijk A, Vinks SA, Blankestijn PJ, Savelkoul JF, Meulenbelt J, Boereboom FT: Pharmacokinetics and dosing regimen of meropenem in critically ill patients receiving continuous venovenous hemofiltration. Crit Care Med 2000, 28: 3412-3416. 10.1097/00003246-200010000-00006PubMedCrossRef Ververs TF, van Dijk A, Vinks SA, Blankestijn PJ, Savelkoul JF, Meulenbelt J, Boereboom FT: Pharmacokinetics and dosing regimen of meropenem in critically ill patients receiving continuous venovenous hemofiltration. Crit Care Med 2000, 28: 3412-3416. 10.1097/00003246-200010000-00006PubMedCrossRef
23.
go back to reference Krueger WA, Schroeder TH, Hutchison M, Hoffmann E, Dieterich HJ, Heininger A, Erley C, Wehrle A, Unertl K: Pharmacokinetics of meropenem in critically ill patients with acute renal failure treated by continuous hemodiafiltration. Antimicrob Agents Chemother 1998, 42: 2421-2424.PubMedPubMedCentral Krueger WA, Schroeder TH, Hutchison M, Hoffmann E, Dieterich HJ, Heininger A, Erley C, Wehrle A, Unertl K: Pharmacokinetics of meropenem in critically ill patients with acute renal failure treated by continuous hemodiafiltration. Antimicrob Agents Chemother 1998, 42: 2421-2424.PubMedPubMedCentral
24.
go back to reference Valtonen M, Tiula E, Takkunen O, Backman JT, Neuvonen PJ: Elimination of the piperacillin/tazobactam combination during continuous venovenous haemofiltration and haemodiafiltration in patients with acute renal failure. J Antimicrob Chemother 2001, 48: 881-885. 10.1093/jac/48.6.881PubMedCrossRef Valtonen M, Tiula E, Takkunen O, Backman JT, Neuvonen PJ: Elimination of the piperacillin/tazobactam combination during continuous venovenous haemofiltration and haemodiafiltration in patients with acute renal failure. J Antimicrob Chemother 2001, 48: 881-885. 10.1093/jac/48.6.881PubMedCrossRef
25.
go back to reference Gangireddy VGR, Mitchell LC, Coleman T: Cefepime neurotoxicity despite renal adjusted dosing. Scand J Infect Dis 2011, 43: 827-829. 10.3109/00365548.2011.581308PubMedCrossRef Gangireddy VGR, Mitchell LC, Coleman T: Cefepime neurotoxicity despite renal adjusted dosing. Scand J Infect Dis 2011, 43: 827-829. 10.3109/00365548.2011.581308PubMedCrossRef
26.
go back to reference Huang WT, Hsu YJ, Chu PL, Lin SH: Neurotoxicity associated with standard doses of piperacillin in an elderly patient with renal failure. Infection 2009, 37: 374-376. 10.1007/s15010-009-8373-3PubMedCrossRef Huang WT, Hsu YJ, Chu PL, Lin SH: Neurotoxicity associated with standard doses of piperacillin in an elderly patient with renal failure. Infection 2009, 37: 374-376. 10.1007/s15010-009-8373-3PubMedCrossRef
27.
go back to reference Maganti R, Jolin D, Rishi D, Biswas A: Nonconvulsive status epilepticus due to cefepime in a patient with normal renal function. Epilepsy Behav 2006, 8: 312-314. 10.1016/j.yebeh.2005.09.010PubMedCrossRef Maganti R, Jolin D, Rishi D, Biswas A: Nonconvulsive status epilepticus due to cefepime in a patient with normal renal function. Epilepsy Behav 2006, 8: 312-314. 10.1016/j.yebeh.2005.09.010PubMedCrossRef
28.
go back to reference Klion AD, Kallsen J, Cowl CT, Nauseef WM: Ceftazidime-related nonconvulsive status epilepticus. Arch Int Med 1994, 154: 586-589. 10.1001/archinte.1994.00420050158014CrossRef Klion AD, Kallsen J, Cowl CT, Nauseef WM: Ceftazidime-related nonconvulsive status epilepticus. Arch Int Med 1994, 154: 586-589. 10.1001/archinte.1994.00420050158014CrossRef
29.
go back to reference Smith NL, Freebairn RC, Park MA, Wallis SC, Roberts JA, Lipman J: Therapeutic drug monitoring when using cefepime in continuous renal replacement therapy: seizures associated with cefepime. Critical Care Resusc 2012, 14: 312-315. Smith NL, Freebairn RC, Park MA, Wallis SC, Roberts JA, Lipman J: Therapeutic drug monitoring when using cefepime in continuous renal replacement therapy: seizures associated with cefepime. Critical Care Resusc 2012, 14: 312-315.
30.
go back to reference Chapuis TM, Giannoni E, Majcherczyk PA, Chioléro R, Schaller MD, Berger MM, Bolay S, Décosterd LA, Bugnon D, Moreillon P: Prospective monitoring of cefepime in intensive care unit adult patients. Crit Care 2010, 14: R51. 10.1186/cc8941PubMedPubMedCentralCrossRef Chapuis TM, Giannoni E, Majcherczyk PA, Chioléro R, Schaller MD, Berger MM, Bolay S, Décosterd LA, Bugnon D, Moreillon P: Prospective monitoring of cefepime in intensive care unit adult patients. Crit Care 2010, 14: R51. 10.1186/cc8941PubMedPubMedCentralCrossRef
31.
go back to reference Covajes C, Scolletta S, Penaccini L, Ocampos-Martinez E, Abdelhadii A, Beumier M, Jacobs F, de Backer D, Vincent JL, Taccone FS: Continuous infusion of vancomycin in septic patients receiving continuous renal replacement therapy. Intern J Antimicrob Agents 2013, 41: 261-266. 10.1016/j.ijantimicag.2012.10.018CrossRef Covajes C, Scolletta S, Penaccini L, Ocampos-Martinez E, Abdelhadii A, Beumier M, Jacobs F, de Backer D, Vincent JL, Taccone FS: Continuous infusion of vancomycin in septic patients receiving continuous renal replacement therapy. Intern J Antimicrob Agents 2013, 41: 261-266. 10.1016/j.ijantimicag.2012.10.018CrossRef
32.
go back to reference Arzuaga A, Isla A, Gascón AR, Maynar J, Corral E, Pedraz JL: Elimination of piperacillin and tazobactam by renal replacement therapies with AN69 and polysulfone hemofilters: evaluation of the sieving coefficient. Blood Purif 2006, 24: 347-354. 10.1159/000092921PubMedCrossRef Arzuaga A, Isla A, Gascón AR, Maynar J, Corral E, Pedraz JL: Elimination of piperacillin and tazobactam by renal replacement therapies with AN69 and polysulfone hemofilters: evaluation of the sieving coefficient. Blood Purif 2006, 24: 347-354. 10.1159/000092921PubMedCrossRef
33.
go back to reference McKinnon PS, Paladino JA, Schentag JJ: Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T > MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections. Int J Antimicrob Agents 2008, 31: 345-351. 10.1016/j.ijantimicag.2007.12.009PubMedCrossRef McKinnon PS, Paladino JA, Schentag JJ: Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T > MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections. Int J Antimicrob Agents 2008, 31: 345-351. 10.1016/j.ijantimicag.2007.12.009PubMedCrossRef
34.
go back to reference Tam VH, McKinnon PS, Akins RL, Rybak MJ, Drusano GL: Pharmacodynamics of cefepime in patients with Gram-negative infections. J Antimicrob Chemother 2002, 50: 425-428. 10.1093/jac/dkf130PubMedCrossRef Tam VH, McKinnon PS, Akins RL, Rybak MJ, Drusano GL: Pharmacodynamics of cefepime in patients with Gram-negative infections. J Antimicrob Chemother 2002, 50: 425-428. 10.1093/jac/dkf130PubMedCrossRef
35.
go back to reference Wong G, Brinkman A, Benefield RJ, Carlier M, De Waele JJ, El Helali N, Frey O, Harbarth S, Huttner A, McWhinney B, Misset B, Pea F, Preisenberger J, Roberts MS, Robertson TA, Roehr A, Sime FB, Taccone FS, Ungerer JP, Lipman J, Roberts JA: An international, multicentre survey of β-lactam antibiotic therapeutic drug monitoring practice in intensive care units. J Antimicrob Chemother 2014. Epub ahead of print Wong G, Brinkman A, Benefield RJ, Carlier M, De Waele JJ, El Helali N, Frey O, Harbarth S, Huttner A, McWhinney B, Misset B, Pea F, Preisenberger J, Roberts MS, Robertson TA, Roehr A, Sime FB, Taccone FS, Ungerer JP, Lipman J, Roberts JA: An international, multicentre survey of β-lactam antibiotic therapeutic drug monitoring practice in intensive care units. J Antimicrob Chemother 2014. Epub ahead of print
36.
go back to reference Nicasio AM, Eagye KJ, Kuti EL, Nicolau DP, Kuti JL: Length of stay and hospital costs associated with a pharmacodynamic-based clinical pathway for empiric antibiotic choice for ventilator-associated pneumonia. Pharmacotherapy 2010, 30: 453-462. 10.1592/phco.30.5.453PubMedCrossRef Nicasio AM, Eagye KJ, Kuti EL, Nicolau DP, Kuti JL: Length of stay and hospital costs associated with a pharmacodynamic-based clinical pathway for empiric antibiotic choice for ventilator-associated pneumonia. Pharmacotherapy 2010, 30: 453-462. 10.1592/phco.30.5.453PubMedCrossRef
37.
go back to reference Goncalves-Pereira J, Paiva JA: Dose modulation: a new concept of antibiotic therapy in the critically ill patient? J Crit Care 2013, 28: 341-346. 10.1016/j.jcrc.2012.11.018PubMedCrossRef Goncalves-Pereira J, Paiva JA: Dose modulation: a new concept of antibiotic therapy in the critically ill patient? J Crit Care 2013, 28: 341-346. 10.1016/j.jcrc.2012.11.018PubMedCrossRef
Metadata
Title
β-lactam antibiotic concentrations during continuous renal replacement therapy
Authors
Marjorie Beumier
Giuseppe Stefano Casu
Maya Hites
Lucie Seyler
Frederic Cotton
Jean-Louis Vincent
Frédérique Jacobs
Fabio Silvio Taccone
Publication date
01-06-2014
Publisher
BioMed Central
Published in
Critical Care / Issue 3/2014
Electronic ISSN: 1364-8535
DOI
https://doi.org/10.1186/cc13886

Other articles of this Issue 3/2014

Critical Care 3/2014 Go to the issue